Spyre Therapeutics, Inc. announced a strategic expansion of its SPY002 program into rheumatoid arthritis (RA), with a Phase 2 RA trial anticipated to initiate in mid-2025 and topline results expected in 2026. This broadens the potential market opportunity for its next-generation antibody therapeutics.
The company also highlighted key 2025 priorities, including expected Phase 1 interim results for SPY002 in the second quarter of 2025 and for SPY003 in the second half of 2025. A Phase 2 platform trial in ulcerative colitis (UC) remains on track for initiation in mid-2025, evaluating SPY001, SPY002, SPY003, and combinations, with initial results expected in 2026.
As of December 31, 2024, Spyre reported a preliminary cash, cash equivalents, and marketable securities balance of over $600 million. This strong financial position is anticipated to provide a cash runway into the second half of 2028, supporting the extensive clinical development plan.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.